Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

UCB Acquiring Celltech; Phase III TNF Inhibitor At Center Of $2.7 Bil. Deal

  • News

Executive Summary

UCB is paying $2.7 bil. to lock up rights to Celltech's TNF inhibitor CDP-870

You may also be interested in...



Pfizer Considering Biotech Acquisitions; “Probably No” Big Mergers

Pfizer is returning to acquisition mode, but with an eye on building its biotechnology presence rather than another major pharmaceutical merger

Pharmacia R&D Head Ando Leaves For Celltech; Will Still Work With Pfizer

Pharmacia R&D President Goran Ando, MD, will move to the other side of a partnership between Pharmacia and Celltech for the Phase III rheumatoid arthritis agent CDP-870 as Celltech CEO

Abbott Humira Marketing Will Challenge RA Competitors On Dosing, Efficacy

Abbott will highlight Humira dosing convenience, efficacy and price to encourage switching of rheumatoid arthritis patients from Amgen/Wyeth's Enbrel or Johnson & Johnson's Remicade

Table

View full table

Tags:
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS044049

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By